OncoMed Pharmaceuticals Financials

OncoMed Pharmaceuticals Stock Summary

OncoMed Pharmaceuticals competes with Vince Holding, Shoe Carnival, Comstock Holding, SEI Investments, and Zumiez. OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancers growth, resistance, recurrence, and metastasis. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California. OncoMed Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 22 people.

OncoMed Pharmaceuticals Key Financial Ratios

Generally speaking, OncoMed Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from OncoMed Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of OncoMed Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that OncoMed Pharmaceuticals reports annually and quarterly.

OncoMed Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining OncoMed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare OncoMed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across OncoMed Pharmaceuticals competition to find correlations between indicators driving OncoMed Pharmaceuticals's intrinsic value. More Info.OncoMed Pharmaceuticals is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value OncoMed Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for OncoMed Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the OncoMed Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the OncoMed Pharmaceuticals information on this page should be used as a complementary analysis to other OncoMed Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

If you are still planning to invest in OncoMed Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoMed Pharmaceuticals' history and understand the potential risks before investing.